ClinicalTrials.gg
CompletedNCT00219557Updated May 14, 2019Results posted

AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer

A Phase 2 interventional study of Gemcitabine and AG-013736 in Pancreatic Neoplasms, sponsored by Pfizer. Completed at 38 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-14.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Pancreatic Neoplasms by Pfizer — 3 open to participants now, 4 under way, 1 of them phase 3. Pancreatic Neoplasms · Pfizer.

Enrollment
9th of 24
111 · median 79
Started
2005
the only one that year
Phase 2
7 of 25
none open now
Registered
3rd of 25
by date

Among the 25 studies in Pancreatic Neoplasms by Pfizer, this one is the 9th largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2005, is one of 7 in phase 2, and was the 3rd registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

3 of the 25 studies in Pancreatic Neoplasms by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Pancreatic Neoplasms by Pfizer, or all of them as a file.
02

Study summary

This is a Phase 2 study being conducted at multiple centers in the United States, Europe and Canada. Patients having pancreatic cancer that is locally advanced or that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have not had any prior systemic treatment for advanced disease. The purpose of the study is to test whether the angiogenesis inhibitor Axitinib [AG-013736] in combination with gemcitabine is an effective treatment for advanced pancreatic cancer vs. gemcitabine alone by overall survival.

03

Conditions studied

  • Pancreatic Neoplasms

Keywords

  • Randomized Phase 2 Study of AG-013736 in Combination with Gemcitabine versus Gemcitabine Alone in Advanced Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with advanced (localized but surgically unresectable or ) histologically/ proven epithelial cancer of the exocrine pancreas
  • no prior therapy for metastatic disease

Exclusion criteria

Exclusion Criteria:

  • patients with locally advanced disease who are candidates for radiation therapy.
  • uncontrolled (a controlled brain metastasis must be previously treated, asymptomatic, and without growth for 4 months)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
111 participants (actual)

Study arms

  • Active comparator
    Gemcitabine

    Drug: Gemcitabine

  • Experimental
    Axitinib [AG-013736] plus gemcitabine

    Drug: AG-013736 · Drug: Gemcitabine

Interventions

  • Gemcitabine 1000 mg/m\^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks

  • Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 4 weeks.

  • Gemcitabine 1000 mg/m\^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Time in days from randomization to date of death due to any cause. OS was calculated as the death date minus the date of randomization plus 1. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).

    Time frame: Baseline of Phase 2 to death or until at least 1 year after the randomization of the last participant

Secondary outcomes

  1. Dose Confirmation of Axitinib (AG-013736) on Basis of Number of Participants With Dose Limiting Toxicity (DLT)

    Dose of axitinib (AG-013736) was confirmed if not more than 1 out of 6 participants experienced a DLT during first cycle. DLT included grade (Gr) 4 neutropenia or thrombocytopenia, greater than or equal to (\>=) Gr 3 anemia or non hematological toxicities for \>= 7 days (except alopecia) or \>= Gr 1 hemoptysis or \>=2 gram /24 hours proteinuria or inability to resume background chemotherapy or axitinib (AG-013736) dosing within 14 days of stopping due to treatment related toxicity.

    Time frame: Phase 1 baseline up to Week 4

  2. Dose Confirmation of Gemcitabine on Basis of Number of Participants With Dose Limiting Toxicity (DLT)

    Dose of gemcitabine was confirmed if not more than 1 out of 6 participants experienced a DLT during first cycle. DLT included grade (Gr) 4 neutropenia or thrombocytopenia, greater than or equal to (\>=) Gr 3 anemia or non hematological toxicities for \>= 7 days (except alopecia) or \>= Gr 1 hemoptysis or \>=2 gram /24 hours proteinuria or inability to resume background chemotherapy or axitinib (AG-013736) dosing within 14 days of stopping due to treatment related toxicity.

    Time frame: Phase 1 Baseline up to Week 4

  3. Maximum Observed Plasma Concentration (Cmax) for Axitinib (AG-013736)

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 3.5, 4.5, 9.5, and 12.5 hours (hr) post-dose on Day 15 of Phase 1 Cycle 1

  4. Area Under the Curve From Time Zero to 24 Hours [AUC (0-24)] of Axitinib (AG-013736)

    AUC (0-24) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to 24 hours (0-24).

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 3.5, 4.5, 9.5, and 12.5 hr post-dose on Day 15 of Phase 1 Cycle 1

  5. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Axitinib (AG-013736)

    Tmax was based on the actual time points when the samples were collected.

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 3.5, 4.5, 9.5, and 12.5 hr post-dose on Day 15 of Phase 1 Cycle 1

  6. Plasma Decay Half-life (t1/2) of Axitinib (AG-013736)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 3.5, 4.5, 9.5, and 12.5 hr post-dose on Day 15 of Phase 1 Cycle 1

  7. Maximum Observed Plasma Concentration (Cmax) of Gemcitabine

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 9 and 12 hr after start of infusion on Day 15 of Phase 1 Cycle 1

  8. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Gemcitabine

    AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 9 and 12 hr after start of infusion on Day 15 of Phase 1 Cycle 1

  9. Plasma Decay Half-life (t1/2) of Gemcitabine

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 9 and 12 hr after start of infusion on Day 15 of Phase 1 Cycle 1

  10. Population Pharmacokinetics of Axitinib (AG-013736) in Phase 2

    Data for this outcome measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

    Time frame: Phase 2 Day 1 (Pre-dose), Day 29, Day 57 and then every 8 weeks until disease progression or discontinuation from study or up to 80 weeks

  11. Percentage of Participants With Overall Response (OR)

    Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non-target). PR are those with at least 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum of longest dimensions.

    Time frame: Phase 2 baseline to disease progression or discontinuation from study, assessed every 8 weeks up to 80 weeks

  12. Duration of Response (DR)

    Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

    Time frame: Phase 2 baseline to disease progression or discontinuation from study due to any cause, assessed every 8 weeks up to 80 weeks

  13. Progression-free Survival (PFS)

    Time in days from randomization to first documentation of objective tumor progression or death due to any cause. PFS was calculated as first event date minus the date of randomization plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").

    Time frame: Phase 2 baseline until the date of first documented progression or death due to any cause, assessed every 8 weeks up to 80 weeks

  14. One Year Survival Probability

    One year survival probability was defined as the probability of survival at one year after the date of randomization based on the Kaplan Meier estimate.

    Time frame: Phase 2 baseline to disease progression or death due to any cause or at least 1 year after the first dose for the last participant

  15. Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score at Day 1 of Every Cycle and End of Study

    EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms. Change from baseline=Cycle/Day score minus baseline score.

    Time frame: Phase 2 baseline [Day (D)1 of Cycle (C)1], Day 1 of all subsequent cycles up to Cycle 14 and end of study (EoS).

  16. Change From Baseline in 26-item Pancreatic Cancer-specific Quality of Life Questionnaire (QLQ-PAN26) Score at Day 1 of Every Cycle and End of Study

    QLQ-PAN26 consists of 26 questions (Qs) relating to disease symptoms, treatment (Tx) side effects and emotional issues specific to pancreatic cancer (PC). Questions include on altered bowel habits, pain, dietary changes, disease and Tx-related symptoms and issues related to the emotional and social well-being of participants with PC. All 26 Qs are answered on 4-point Likert scale ranging from '1=not at all' to 4='very much' and subsequently transformed into scales that range from 0-100. Higher scores on functioning scales=better functioning; higher scores on the symptom scales=more symptoms.

    Time frame: Phase 2 baseline [Day (D) 1 of Cycle (C)1], Day 1 of all subsequent cycles up to Cycle 14 and end of study (EoS).

07

Results

Posted Aug 24, 2012
Limitations and caveats
Population pharmacokinetics was not presented, as the data was not available for the single study and data of other axitinib (AG-013736) Phase 2 studies would be pooled together in a separate report.

Participant flow

Phase 1
Participant flow — Phase 1
MilestoneAxitinib + Gemcitabine (Phase 1 Lead-In)Axitinib + GemcitabineGemcitabine
Started800
Completed100
Not completed700
Withdrew: Lack of efficacy300
Withdrew: Adverse event200
Withdrew: Withdrawal by subject100
Withdrew: Started chemotherapy at other institute100
Phase 2
Participant flow — Phase 2
MilestoneAxitinib + Gemcitabine (Phase 1 Lead-In)Axitinib + GemcitabineGemcitabine
Started06934
Treated06831
Completed001
Not completed06933
Withdrew: Lack of efficacy02115
Withdrew: Adverse event0222
Withdrew: Death082
Withdrew: Other086
Withdrew: Withdrawal by subject095
Withdrew: Treatment not received013

Outcome measures

PrimaryOverall Survival (OS)

Time in days from randomization to date of death due to any cause. OS was calculated as the death date minus the date of randomization plus 1. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).

Time frame:
Baseline of Phase 2 to death or until at least 1 year after the randomization of the last participant
Reported as:
Median · Days
Overall Survival (OS)
DaysAxitinib + GemcitabineGemcitabine
Overall Survival (OS)210 (162 to 308)171 (125 to 267)
Statistical analysis
  • Axitinib + Gemcitabine vs Gemcitabine · Log Rank · p = 0.1026 (One-sided log-rank test at alpha = 0.1 significance level was used.) · Hazard ratio (hr): 0.758 · 95% CI 0.490 to 1.170
SecondaryDose Confirmation of Axitinib (AG-013736) on Basis of Number of Participants With Dose Limiting Toxicity (DLT)

Dose of axitinib (AG-013736) was confirmed if not more than 1 out of 6 participants experienced a DLT during first cycle. DLT included grade (Gr) 4 neutropenia or thrombocytopenia, greater than or equal to (\>=) Gr 3 anemia or non hematological toxicities for \>= 7 days (except alopecia) or \>= Gr 1 hemoptysis or \>=2 gram /24 hours proteinuria or inability to resume background chemotherapy or axitinib (AG-013736) dosing within 14 days of stopping due to treatment related toxicity.

Time frame:
Phase 1 baseline up to Week 4
Reported as:
Number · participants
Dose Confirmation of Axitinib (AG-013736) on Basis of Number of Participants With Dose Limiting Toxicity (DLT)
participantsAxitinib + Gemcitabine (Phase 1 Lead-In)
Dose Confirmation of Axitinib (AG-013736) on Basis of Number of Participants With Dose Limiting Toxicity (DLT)0
SecondaryDose Confirmation of Gemcitabine on Basis of Number of Participants With Dose Limiting Toxicity (DLT)

Dose of gemcitabine was confirmed if not more than 1 out of 6 participants experienced a DLT during first cycle. DLT included grade (Gr) 4 neutropenia or thrombocytopenia, greater than or equal to (\>=) Gr 3 anemia or non hematological toxicities for \>= 7 days (except alopecia) or \>= Gr 1 hemoptysis or \>=2 gram /24 hours proteinuria or inability to resume background chemotherapy or axitinib (AG-013736) dosing within 14 days of stopping due to treatment related toxicity.

Time frame:
Phase 1 Baseline up to Week 4
Reported as:
Number · participants
Dose Confirmation of Gemcitabine on Basis of Number of Participants With Dose Limiting Toxicity (DLT)
participantsAxitinib + Gemcitabine (Phase 1 Lead-In)
Dose Confirmation of Gemcitabine on Basis of Number of Participants With Dose Limiting Toxicity (DLT)0
SecondaryMaximum Observed Plasma Concentration (Cmax) for Axitinib (AG-013736)
Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 3.5, 4.5, 9.5, and 12.5 hours (hr) post-dose on Day 15 of Phase 1 Cycle 1
Reported as:
Mean · nanogram/milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) for Axitinib (AG-013736)
nanogram/milliliter (ng/mL)Axitinib + Gemcitabine (Phase 1 Lead-In)
Maximum Observed Plasma Concentration (Cmax) for Axitinib (AG-013736)45.08 ± 34.32
SecondaryArea Under the Curve From Time Zero to 24 Hours [AUC (0-24)] of Axitinib (AG-013736)

AUC (0-24) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to 24 hours (0-24).

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 3.5, 4.5, 9.5, and 12.5 hr post-dose on Day 15 of Phase 1 Cycle 1
Reported as:
Mean · ng*hr/mL
Area Under the Curve From Time Zero to 24 Hours [AUC (0-24)] of Axitinib (AG-013736)
ng*hr/mLAxitinib + Gemcitabine (Phase 1 Lead-In)
Area Under the Curve From Time Zero to 24 Hours [AUC (0-24)] of Axitinib (AG-013736)282.34 ± 135.27
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of Axitinib (AG-013736)

Tmax was based on the actual time points when the samples were collected.

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 3.5, 4.5, 9.5, and 12.5 hr post-dose on Day 15 of Phase 1 Cycle 1
Reported as:
Median · hr
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Axitinib (AG-013736)
hrAxitinib + Gemcitabine (Phase 1 Lead-In)
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Axitinib (AG-013736)1.52 (0.50 to 2.20)
SecondaryPlasma Decay Half-life (t1/2) of Axitinib (AG-013736)

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 3.5, 4.5, 9.5, and 12.5 hr post-dose on Day 15 of Phase 1 Cycle 1
Reported as:
Mean · hr
Plasma Decay Half-life (t1/2) of Axitinib (AG-013736)
hrAxitinib + Gemcitabine (Phase 1 Lead-In)
Plasma Decay Half-life (t1/2) of Axitinib (AG-013736)2.97 ± 1.95
SecondaryMaximum Observed Plasma Concentration (Cmax) of Gemcitabine
Time frame:
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 9 and 12 hr after start of infusion on Day 15 of Phase 1 Cycle 1
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Gemcitabine
ng/mLAxitinib + Gemcitabine (Phase 1 Lead-In)
Maximum Observed Plasma Concentration (Cmax) of Gemcitabine27280.0 ± 12599.1
SecondaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Gemcitabine

AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Time frame:
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 9 and 12 hr after start of infusion on Day 15 of Phase 1 Cycle 1
Reported as:
Mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Gemcitabine
ng*hr/mLAxitinib + Gemcitabine (Phase 1 Lead-In)
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Gemcitabine13656.00 ± 4142.16
SecondaryPlasma Decay Half-life (t1/2) of Gemcitabine

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 9 and 12 hr after start of infusion on Day 15 of Phase 1 Cycle 1
Reported as:
Mean · hr
Plasma Decay Half-life (t1/2) of Gemcitabine
hrAxitinib + Gemcitabine (Phase 1 Lead-In)
Plasma Decay Half-life (t1/2) of Gemcitabine0.310 ± 0.028
SecondaryPopulation Pharmacokinetics of Axitinib (AG-013736) in Phase 2

Data for this outcome measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

Time frame:
Phase 2 Day 1 (Pre-dose), Day 29, Day 57 and then every 8 weeks until disease progression or discontinuation from study or up to 80 weeks

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Overall Response (OR)

Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non-target). PR are those with at least 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum of longest dimensions.

Time frame:
Phase 2 baseline to disease progression or discontinuation from study, assessed every 8 weeks up to 80 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Overall Response (OR)
Percentage of ParticipantsAxitinib + GemcitabineGemcitabine
Percentage of Participants With Overall Response (OR)7.2 (2.4 to 16.1)2.9 (0.1 to 15.3)
Statistical analysis
  • Axitinib + Gemcitabine vs Gemcitabine · Fisher Exact · p = 0.661 · Difference in response rate: 4.3 · 95% CI -4.0 to 12.7
SecondaryDuration of Response (DR)

Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

Time frame:
Phase 2 baseline to disease progression or discontinuation from study due to any cause, assessed every 8 weeks up to 80 weeks
Reported as:
Median · Days
Duration of Response (DR)
DaysAxitinib + GemcitabineGemcitabine
Duration of Response (DR)379 (136 to 379)155 (NA to NA)
SecondaryProgression-free Survival (PFS)

Time in days from randomization to first documentation of objective tumor progression or death due to any cause. PFS was calculated as first event date minus the date of randomization plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").

Time frame:
Phase 2 baseline until the date of first documented progression or death due to any cause, assessed every 8 weeks up to 80 weeks
Reported as:
Number · Days
Progression-free Survival (PFS)
DaysAxitinib + GemcitabineGemcitabine
Progression-free Survival (PFS)116 (109 to 160)113 (68 to 205)
Statistical analysis
  • Axitinib + Gemcitabine vs Gemcitabine · Log Rank · p = 0.4466 (One-sided log-rank test at alpha = 0.1 significance level was used.) · Hazard ratio (hr): 0.9648 · 95% CI 0.5400 to 1.7300
SecondaryOne Year Survival Probability

One year survival probability was defined as the probability of survival at one year after the date of randomization based on the Kaplan Meier estimate.

Time frame:
Phase 2 baseline to disease progression or death due to any cause or at least 1 year after the first dose for the last participant
Reported as:
Number · Percent chance of survival
One Year Survival Probability
Percent chance of survivalAxitinib + GemcitabineGemcitabine
One Year Survival Probability36.81 (25.71 to 47.93)23.53 (11.48 to 38.01)
SecondaryChange From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score at Day 1 of Every Cycle and End of Study

EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms. Change from baseline=Cycle/Day score minus baseline score.

Time frame:
Phase 2 baseline [Day (D)1 of Cycle (C)1], Day 1 of all subsequent cycles up to Cycle 14 and end of study (EoS).
Reported as:
Mean · units on a scale
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score at Day 1 of Every Cycle and End of Study
units on a scaleAxitinib + GemcitabineGemcitabine
Global QoL: Baseline55.60 ± 27.1854.32 ± 21.10
Physical Functioning: Baseline76.90 ± 24.7382.22 ± 14.44
Role Functioning: Baseline62.56 ± 33.2160.26 ± 35.30
Emotional Functioning: Baseline67.22 ± 26.1766.98 ± 23.96
Cognitive Functioning: Baseline82.82 ± 23.9382.10 ± 19.57
Social Functioning: Baseline67.44 ± 33.0070.51 ± 29.56
Fatigue: Baseline43.50 ± 29.7842.80 ± 25.73
Nausea and Vomiting: Baseline19.74 ± 28.2413.58 ± 20.17
Pain: Baseline40.00 ± 33.3137.04 ± 31.80
Dyspnea: Baseline12.50 ± 21.8216.05 ± 26.75
Insomnia: Baseline31.28 ± 31.6639.51 ± 39.26
Appetite loss: Baseline41.03 ± 40.3033.33 ± 34.59
Constipation: Baseline34.87 ± 37.9338.27 ± 38.90
Diarrhea: Baseline20.00 ± 27.5116.05 ± 28.30
Financial Difficulties: Baseline10.42 ± 19.5928.40 ± 41.04
Global QoL: Change at C2 D1-5.10 ± 21.173.33 ± 16.97
Physical Functioning: Change at C2 D1-5.07 ± 18.850.95 ± 16.23
Role Functioning: Change at C2 D10.33 ± 25.939.65 ± 29.56
Emotional Functioning: Change at C2 D13.21 ± 21.347.94 ± 17.77
Cognitive Functioning: Change at C2 D1-3.53 ± 21.481.59 ± 18.93
Social Functioning: Change at C2 D1-4.17 ± 29.50-0.83 ± 28.85
Fatigue: Change at C2 D11.42 ± 21.74-8.99 ± 26.67
Nausea and Vomiting: Change at C2 D1-5.88 ± 26.84-1.59 ± 12.81
Pain: Change at C2 D1-9.29 ± 27.89-16.67 ± 31.62
Dyspnea: Change at C2 D19.33 ± 26.97-3.17 ± 25.61
Insomnia: Change at C2 D1-9.15 ± 28.35-19.05 ± 34.27
Appetite loss: Change at C2 D1-0.65 ± 35.58-14.29 ± 35.86
Constipation: Change at C2 D1-9.62 ± 32.56-14.29 ± 29.00
Diarrhea: Change at C2 D1-1.28 ± 29.490.00 ± 18.26
Financial Difficulties: Change at C2 D10.67 ± 19.62-4.76 ± 19.11
Global QoL: Change at C3 D1-9.17 ± 30.366.67 ± 15.17
Physical Functioning: Change at C3 D1-8.13 ± 21.463.44 ± 18.73
Role Functioning: Change at C3 D1-5.56 ± 27.7113.10 ± 25.47
Emotional Functioning: Change at C3 D1-1.69 ± 26.8012.22 ± 19.89
Cognitive Functioning: Change at C3 D1-4.88 ± 24.792.22 ± 16.51
Social Functioning: Change at C3 D1-4.07 ± 32.665.56 ± 24.93
Fatigue: Change at C3 D17.41 ± 28.61-8.73 ± 26.57
Nausea and Vomiting: Change at C3 D1-4.37 ± 29.00-2.56 ± 16.45
Pain: Change at C3 D1-6.75 ± 33.75-23.33 ± 30.08
Dyspnea: Change at C3 D13.25 ± 27.69-7.14 ± 19.30
Insomnia: Change at C3 D1-10.32 ± 34.13-11.90 ± 38.36
Appetite loss: Change at C3 D111.11 ± 39.42-5.13 ± 29.96
Constipation: Change at C3 D1-10.57 ± 32.86-13.33 ± 35.19
Diarrhea: Change at C3 D17.32 ± 32.074.44 ± 30.52
Financial Difficulties: Change at C3 D13.33 ± 24.81-2.22 ± 26.63
Global QoL: Change at C4 D1-6.67 ± 21.04-1.03 ± 15.27
Physical Functioning: Change at C4 D1-6.67 ± 23.15-1.03 ± 15.36
Role Functioning: Change at C4 D1-7.81 ± 29.639.72 ± 36.56
Emotional Functioning: Change at C4 D1-3.23 ± 22.649.03 ± 36.56
Cognitive Functioning: Change at C4 D1-6.99 ± 25.740.00 ± 15.89
Social Functioning: Change at C4 D1-8.60 ± 35.45-1.52 ± 24.10
Fatigue: Change at C4 D17.47 ± 25.19-3.42 ± 25.41
Nausea and Vomiting: Change at C4 D1-4.69 ± 19.966.41 ± 18.68
Pain: Change at C4 D1-16.67 ± 29.02-11.54 ± 28.37
Dyspnea: Change at C4 D10.00 ± 28.54-5.13 ± 29.96
Insomnia: Change at C4 D1-11.46 ± 28.85-5.13 ± 32.90
Appetite loss: Change at C4 D16.25 ± 36.35-2.78 ± 33.21
Constipation: Change at C4 D1-24.44 ± 37.07-25.00 ± 40.51
Diarrhea: Change at C4 D17.53 ± 39.175.56 ± 34.33
Financial Difficulties: Change at C4 D11.15 ± 22.68-8.33 ± 20.72
Global QoL: Change at C5 D1-9.29 ± 27.8210.71 ± 21.36
Physical Functioning: Change at C5 D1-8.57 ± 23.080.00 ± 22.25
Role Functioning: Change at C5 D1-8.93 ± 29.227.14 ± 28.64
Emotional Functioning: Change at C5 D1-3.87 ± 22.9620.24 ± 14.32
Cognitive Functioning: Change at C5 D1-2.38 ± 24.737.14 ± 16.27
Social Functioning: Change at C5 D1-15.48 ± 33.924.76 ± 23.00
Fatigue: Change at C5 D19.72 ± 28.59-15.28 ± 17.76
Nausea and Vomiting: Change at C5 D10.00 ± 26.06-6.25 ± 15.27
Pain: Change at C5 D1-5.36 ± 34.26-25.00 ± 26.73
Dyspnea: Change at C5 D19.52 ± 27.00-12.50 ± 24.80
Insomnia: Change at C5 D1-19.05 ± 35.63-29.17 ± 33.03
Appetite loss: Change at C5 D10.00 ± 42.55-20.83 ± 43.42
Constipation: Change at C5 D1-21.43 ± 35.39-33.33 ± 38.49
Diarrhea: Change at C5 D17.14 ± 33.16-4.76 ± 29.99
Financial Difficulties: Change at C5 D10.00 ± 22.650.00 ± 36.51
Global QoL: Change at C6 D1-14.22 ± 20.36-5.56 ± 12.73
Physical Functioning: Change at C6 D1-6.32 ± 25.386.67 ± 18.86
Role Functioning: Change at C6 D1-9.65 ± 27.9516.67 ± 47.14
Emotional Functioning: Change at C6 D12.19 ± 15.928.33 ± 14.43
Cognitive Functioning: Change at C6 D1-0.88 ± 18.8211.11 ± 9.62
Social Functioning: Change at C6 D1-2.63 ± 27.92-16.67 ± 16.67
Fatigue: Change at C6 D16.73 ± 24.19-16.67 ± 39.28
Nausea and Vomiting: Change at C6 D1-4.39 ± 22.80-8.33 ± 11.79
Pain: Change at C6 D1-8.77 ± 30.11-33.33 ± 16.67
Dyspnea: Change at C6 D1(n=18,2)-1.85 ± 21.300.00 ± 47.14
Insomnia: Change at C6 D1-7.02 ± 30.59-16.67 ± 23.57
Appetite loss: Change at C6 D1(n=19,2)-3.51 ± 53.16-16.67 ± 70.71
Constipation: Change at C6 D1-10.53 ± 35.23-33.33 ± 33.33
Diarrhea: Change at C6 D1-1.75 ± 28.270.00 ± 33.33
Financial Difficulties: Change at C6 D11.75 ± 13.49-22.22 ± 38.49
Global QoL: Change at C7 D1-4.63 ± 37.76-16.67 ± 14.43
Physical Functioning: Change at C7 D1-3.33 ± 24.80-22.22 ± 36.72
Role Functioning: Change at C7 D1-15.00 ± 30.8833.33 ± 70.71
Emotional Functioning: Change at C7 D1-8.33 ± 13.03-7.41 ± 21.58
Cognitive Functioning: Change at C7 D11.67 ± 24.15-5.56 ± 9.62
Social Functioning: Change at C7 D1-15.00 ± 41.16-25.00 ± 11.79
Fatigue: Change at C7 D1-2.22 ± 25.0114.81 ± 42.07
Nausea and Vomiting: Change at C7D11.67 ± 21.4416.67 ± 0.00
Pain: Change at C7 D1-3.33 ± 32.20-11.11 ± 41.94
Dyspnea: Change at C7 D116.67 ± 23.5733.33 ± 33.33
Insomnia: Change at C7 D1-10.00 ± 35.3111.11 ± 38.49
Appetite loss: Change at C7 D1-10.00 ± 58.9022.22 ± 50.92
Constipation: Change at C7 D1-13.33 ± 47.66-66.67 ± 57.74
Diarrhea: Change at C7 D13.33 ± 29.190.00 ± 0.00
Financial Difficulties: Change at C7 D1-6.67 ± 21.080.00 ± 0.00
Global QoL: Change at C8 D1-12.50 ± 33.62-33.33 ± NA
Physical Functioning Change at C8 D1-10.67 ± 22.71-20.00 ± NA
Role Functioning: Change at C8 D1-13.33 ± 23.31-33.33 ± NA
Emotional Functioning: Change at C8 D1-7.50 ± 18.610.00 ± NA
Cognitive Functioning: Change at C8 D10.00 ± 22.22-16.67 ± NA
Social Functioning: Change at C8 D1-11.67 ± 34.29-16.67 ± NA
Fatigue: Change at C8 D14.44 ± 25.232.22 ± NA
Nausea and Vomiting: Change at C8 D10.00 ± 19.2516.67 ± NA
Pain: Change at C8 D1-8.33 ± 37.06-16.67 ± NA
Dyspnea: Change at C8 D114.81 ± 29.4033.33 ± NA
Insomnia: Change at C8 D1-20.00 ± 47.660.00 ± NA
Appetite loss: Change at C8 D1-3.33 ± 48.3033.33 ± NA
Constipation: Change at C8 D1-3.33 ± 29.190.00 ± NA
Diarrhea: Change at C8 D16.67 ± 37.84-66.67 ± NA
Financial Difficulties: Change at C8 D1-3.33 ± 18.920.00 ± NA
Global QoL: Change at C9 D1-17.71 ± 36.03-33.33 ± NA
Physical Functioning: Change at C9 D1-6.67 ± 20.16-40.00 ± NA
Role Functioning: Change at C9 D1-29.17 ± 24.80-33.33 ± NA
Emotional Functioning: Change at C9 D1-3.13 ± 13.32-8.33 ± NA
Cognitive Functioning: Change at C9 D1-2.08 ± 28.78-33.33 ± NA
Social Functioning: Change at C9 D1-6.25 ± 47.09-33.33 ± NA
Fatigue: Change at C9 D118.06 ± 33.5633.33 ± NA
Nausea and Vomiting: Change at C9 D1-8.33 ± 17.8216.67 ± NA
Pain: Change at C9 D10.00 ± 30.860.00 ± NA
Dyspnea: Change at C9 D119.05 ± 26.2333.33 ± NA
Insomnia: Change at C9 D1-4.17 ± 33.030.00 ± NA
Appetite loss: Change at C9 D18.33 ± 63.6233.33 ± NA
Constipation: Change at C9 D1-8.33 ± 38.830.00 ± NA
Diarrhea: Change at C9 D112.50 ± 43.42-66.67 ± NA
Financial Difficulties: Change at C9 D1-4.17 ± 21.360.00 ± NA
Global QoL: Change at C10 D1-16.67 ± 21.52-33.33 ± NA
Physical Functioning: Change at C10 D1-19.05 ± 13.01-46.67 ± NA
Role Functioning: Change at C10 D1-23.81 ± 21.21-50.00 ± NA
Emotional Functioning: Change at C10 D1-20.24 ± 23.00-16.67 ± NA
Cognitive Functioning: Change at C10 D1-9.52 ± 21.21-33.33 ± NA
Social Functioning: Change at C10 D1-21.43 ± 31.50-50.00 ± NA
Fatigue: Change at C10 D125.40 ± 24.6155.56 ± NA
Nausea and Vomiting: Change at C10 D10.00 ± 25.4616.67 ± NA
Pain: Change at C10 D111.90 ± 35.6316.67 ± NA
Dyspnea: Change at C10 D122.22 ± 27.2233.33 ± NA
Insomnia: Change at C10 D14.76 ± 23.000.00 ± NA
Appetite loss: Change at C10 D123.81 ± 46.0033.33 ± NA
Constipation: Change at C10 D1-19.05 ± 37.800.00 ± NA
Diarrhea: Change at C10 D19.52 ± 31.71-66.67 ± NA
Financial Difficulties: Change at C10 D1-4.76 ± 23.000.00 ± NA
Global QoL: Change at C11 D1-38.89 ± 53.58-33.33 ± NA
Physical Functioning: Change at C11 D1-24.44 ± 36.72-40.00 ± NA
Role Functioning: Change at C11 D1-38.89 ± 53.58-66.67 ± NA
Emotional Functioning: Change at C11 D1-25.00 ± 52.04-8.33 ± NA
Cognitive Functioning: Change at C11 D1-27.78 ± 63.10-33.33 ± NA
Social Functioning: Change at C11 D1-38.89 ± 53.58-66.67 ± NA
Fatigue: Change at C11 D137.04 ± 46.2622.22 ± NA
Nausea and Vomiting: Change at C11 D127.78 ± 63.1016.67 ± NA
Pain: Change at C11 D122.22 ± 69.39-16.67 ± NA
Dyspnea: Change at C11 D122.22 ± 69.3933.33 ± NA
Insomnia: Change at C11 D122.22 ± 69.390.00 ± NA
Appetite loss: Change at C11 D144.44 ± 50.920.00 ± NA
Constipation: Change at C11 D10.00 ± 33.330.00 ± NA
Diarrhea: Change at C11 D111.11 ± 19.25-66.67 ± NA
Financial Difficulties: Change at C11 D1-11.11 ± 19.250.00 ± NA
Global QoL: Change at C12 D1-11.11 ± 17.35—
Physical Functioning: Change at C12 D1-6.67 ± 6.67—
Role Functioning: Change at C12 D1-11.11 ± 19.25—
Emotional Functioning: Change at C12 D1-2.78 ± 20.97—
Cognitive Functioning: Change at C12 D10.00 ± 16.67—
Social Functioning: Change at C12 D1-5.56 ± 9.62—
Fatigue: Change at C12 D17.41 ± 12.83—
Nausea and Vomiting: Change at C12 D116.67 ± 60.09—
Pain: Change at C12 D1-5.56 ± 9.62—
Dyspnea: Change at C12 D10.00 ± 0.00—
Insomnia: Change at C12 D1-11.11 ± 19.25—
Appetite loss: Change at C12 D122.22 ± 19.25—
Constipation: Change at C12 D1-22.22 ± 38.49—
Diarrhea: Change at C12 D122.22 ± 19.25—
Financial Difficulties: Change at C12 D1-11.11 ± 19.25—
Global QoL: Change at C13 D1-50.00 ± 35.36—
Physical Functioning: Change at C13 D1-23.33 ± 33.00—
Role Functioning: Change at C13 D1-41.67 ± 35.36—
Emotional Functioning: Change at C13 D1-8.33 ± 11.79—
Cognitive Functioning: Change at C13 D10.00 ± 0.00—
Social Functioning: Change at C13 D1-8.33 ± 35.36—
Fatigue: Change at C13 D133.33 ± 47.14—
Nausea and Vomiting: Change at C13 D1-8.33 ± 35.36—
Pain: Change at C13 D141.67 ± 58.93—
Dyspnea: Change at C13 D10.00 ± NA—
Insomnia: Change at C13 D10.00 ± 0.00—
Appetite loss: Change at C13 D133.33 ± 47.14—
Constipation: Change at C13 D1-16.67 ± 23.57—
Diarrhea: Change at C13 D116.67 ± 23.57—
Financial Difficulties: Change at C13 D1-16.67 ± 23.57—
Global QoL: Change at C14 D1-16.67 ± NA—
Physical Functioning: Change at C14 D1-6.67 ± NA—
Role Functioning: Change at C14 D1-33.33 ± NA—
Emotional Functioning: Change at C14 D1-8.33 ± NA—
Cognitive Functioning: Change at C14 D116.67 ± NA—
Social Functioning: Change at C14 D10.00 ± NA—
Fatigue: Change at C14 D122.22 ± NA—
Nausea and Vomiting: Change at C14 D10.00 ± NA—
Pain: Change at C14 D116.67 ± NA—
Dyspnea: Change at C14 D133.33 ± NA—
Insomnia: Change at C14 D1-33.33 ± NA—
Appetite loss: Change at C14 D10.00 ± NA—
Constipation: Change at C14 D10.00 ± NA—
Diarrhea: Change at C14 D133.33 ± NA—
Financial Difficulties: Change at C14 D1-33.33 ± NA—
Global QoL: Change at EoS-54.17 ± 29.460.00 ± NA
Physical Functioning: Change at EoS-70.00 ± 4.710.00 ± NA
Role Functioning: Change at EoS-33.33 ± 23.570.00 ± NA
Emotional Functioning: Change at EoS-66.67 ± 35.36-25.00 ± NA
Cognitive Functioning: Change at EoS-66.67 ± 0.000.00 ± NA
Social Functioning: Change at EoS-83.33 ± 23.570.00 ± NA
Fatigue: Change at EoS55.56 ± 15.71-11.11 ± NA
Nausea and Vomiting: Change at EoS33.33 ± 23.570.00 ± NA
Pain: Change at EoS41.67 ± 82.5016.67 ± NA
Dyspnea: Change at EoS83.33 ± 23.570.00 ± NA
Insomnia: Change at EoS66.67 ± 47.1433.33 ± NA
Appetite loss: Change at EoS50.00 ± 70.710.00 ± NA
Constipation: Change at EoS-16.67 ± 117.850.00 ± NA
Diarrhea: Change at EoS33.33 ± 47.140.00 ± NA
Financial Difficulties: Change at EoS-16.67 ± 23.570.00 ± NA
Statistical analysis
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -8.44 · 95% CI -19.06 to 2.19
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -6.02 · 95% CI -15.4 to 3.36
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -9.32 · 95% CI -23.77 to 5.12
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -4.73 · 95% CI -15.25 to 5.79
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -5.11 · 95% CI -15.83 to 5.61
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -3.33 · 95% CI -18.72 to 12.06
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 10.41 · 95% CI -1.62 to 22.44
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -4.30 · 95% CI -16.55 to 7.96
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 7.37 · 95% CI -7.57 to 22.32
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 12.51 · 95% CI -1.28 to 26.30
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 9.90 · 95% CI -5.70 to 25.49
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 13.63 · 95% CI -4.81 to 32.07
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 4.67 · 95% CI -11.62 to 20.96
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -1.28 · 95% CI -15.1 to 12.54
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 5.43 · 95% CI -4.67 to 15.53
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -15.83 · 95% CI -32.34 to 0.67
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -11.58 · 95% CI -24.12 to 0.96
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -18.65 · 95% CI -35.47 to -1.83
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -13.92 · 95% CI -29.16 to 1.32
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -7.10 · 95% CI -20.97 to 6.77
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -9.62 · 95% CI -28.28 to 9.04
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 16.14 · 95% CI -1.27 to 33.54
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -1.80 · 95% CI -18.78 to 15.18
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 16.59 · 95% CI -3.22 to 36.39
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 10.39 · 95% CI -5.68 to 26.47
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 1.59 · 95% CI -20.19 to 23.36
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 16.24 · 95% CI -7.62 to 40.1
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 2.76 · 95% CI -17.49 to 23.02
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 2.87 · 95% CI -16.29 to 22.03
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 5.56 · 95% CI -9.81 to 20.92
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -5.97 · 95% CI -19.52 to 7.57
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -5.64 · 95% CI -19.75 to 8.46
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -17.53 · 95% CI -39.11 to 4.05
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -12.25 · 95% CI -26.5 to 2.00
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -6.99 · 95% CI -23.13 to 9.15
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -7.09 · 95% CI -30.48 to 16.31
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 10.88 · 95% CI -5.86 to 27.63
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -11.10 · 95% CI -24.11 to 1.91
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -5.13 · 95% CI -24.26 to 14.00
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 5.13 · 95% CI -14.18 to 24.44
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -6.33 · 95% CI -26.25 to 13.59
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 9.03 · 95% CI -15.26 to 33.32
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 0.56 · 95% CI -25.71 to 26.82
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 1.97 · 95% CI -24.07 to 28.01
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 9.48 · 95% CI -5.89 to 24.86
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -20.01 · 95% CI -43.19 to 3.17
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -8.57 · 95% CI -27.24 to 10.10
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -16.07 · 95% CI -41.10 to 8.96
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -24.11 · 95% CI -42.72 to -5.50
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -9.52 · 95% CI -29.66 to 10.61
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -20.24 · 95% CI -47.93 to 7.46
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 25.00 · 95% CI 3.23 to 46.77
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 6.25 · 95% CI -13.49 to 25.99
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 19.64 · 95% CI -7.12 to 46.41
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 22.02 · 95% CI 0.38 to 43.66
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 10.12 · 95% CI -18.49 to 38.73
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 20.83 · 95% CI -13.98 to 55.65
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 11.90 · 95% CI -19.02 to 42.83
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 11.90 · 95% CI -16.13 to 39.94
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 0.00 · 95% CI -23.38 to 23.38
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -8.66 · 95% CI -34.53 to 17.21
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -12.98 · 95% CI -52.01 to 26.04
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -26.32 · 95% CI -71.87 to 19.24
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -6.14 · 95% CI -26.59 to 14.31
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -11.99 · 95% CI -35.46 to 11.48
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 14.04 · 95% CI -20.97 to 49.04
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 23.39 · 95% CI -15.83 to 62.61
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 3.95 · 95% CI -30.84 to 38.73
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 24.56 · 95% CI -13.08 to 62.20
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -1.85 · 95% CI -38.65 to 34.94
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 9.65 · 95% CI -37.43 to 56.73
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 13.16 · 95% CI -71.22 to 97.54
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 22.81 · 95% CI -22.61 to 68.22
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -1.75 · 95% CI -39.10 to 35.59
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 23.98 · 95% CI 1.09 to 46.86
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 12.04 · 95% CI -39.03 to 63.11
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 18.89 · 95% CI -20.74 to 58.52
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -48.33 · 95% CI -111.94 to 15.28
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -0.93 · 95% CI -22.59 to 20.74
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 7.22 · 95% CI -24.98 to 39.43
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 10.00 · 95% CI -57.71 to 77.71
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -17.04 · 95% CI -58.87 to 24.79
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -15.00 · 95% CI -43.10 to 13.10
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 7.78 · 95% CI -41.75 to 57.30
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -16.67 · 95% CI -53.79 to 20.46
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -21.11 · 95% CI -73.14 to 30.92
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -32.22 · 95% CI -115.58 to 51.13
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 53.33 · 95% CI -18.60 to 125.26
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 3.33 · 95% CI -34.92 to 41.58
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -6.67 · 95% CI -34.3 to 20.96
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 20.83 · 95% CI -58.94 to 100.60
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 9.33 · 95% CI -44.54 to 63.20
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 20.00 · 95% CI -35.30 to 75.30
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -7.50 · 95% CI -51.66 to 36.66
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 16.67 · 95% CI -36.06 to 69.39
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 5.00 · 95% CI -76.36 to 86.36
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -17.78 · 95% CI -77.63 to 42.08
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -16.67 · 95% CI -62.33 to 28.99
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 8.33 · 95% CI -79.59 to 96.26
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -18.52 · 95% CI -89.98 to 52.94
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -20.00 · 95% CI -133.08 to 93.08
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -36.67 · 95% CI -151.27 to 77.94
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -3.33 · 95% CI -72.58 to 65.91
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 73.33 · 95% CI -16.45 to 163.12
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -3.33 · 95% CI -48.23 to 41.56
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 15.62 · 95% CI -74.75 to 106.00
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 33.33 · 95% CI -17.22 to 83.89
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 4.17 · 95% CI -58.04 to 66.37
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 5.21 · 95% CI -28.19 to 38.61
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 31.25 · 95% CI -40.94 to 103.44
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 27.08 · 95% CI -91.02 to 145.18
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -15.28 · 95% CI -99.46 to 68.90
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -25.00 · 95% CI -69.69 to 19.69
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 0.00 · 95% CI -77.40 to 77.40
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -14.29 · 95% CI -82.89 to 54.32
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -4.17 · 95% CI -87.02 to 78.69
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -25.00 · 95% CI -184.57 to 134.57
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -8.33 · 95% CI -105.73 to 89.06
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 79.17 · 95% CI -29.72 to 188.06
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -4.17 · 95% CI -57.74 to 49.41
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 16.67 · 95% CI -39.62 to 72.95
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 27.62 · 95% CI -6.42 to 61.66
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 26.19 · 95% CI -29.28 to 81.66
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -3.57 · 95% CI -63.74 to 56.6
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 23.81 · 95% CI -31.66 to 79.28
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 28.57 · 95% CI -53.82 to 110.96
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -30.16 · 95% CI -94.53 to 34.21
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -16.67 · 95% CI -83.26 to 49.93
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -4.76 · 95% CI -97.98 to 88.45
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -11.11 · 95% CI -86.68 to 64.46
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 4.76 · 95% CI -55.41 to 64.93
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -9.52 · 95% CI -129.86 to 110.82
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -19.05 · 95% CI -117.92 to 79.82
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 76.19 · 95% CI -6.75 to 159.13
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -4.76 · 95% CI -64.93 to 55.41
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -5.56 · 95% CI -271.74 to 260.62
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 15.56 · 95% CI -166.87 to 197.98
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 27.78 · 95% CI -238.4 to 293.96
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -16.67 · 95% CI -275.22 to 241.89
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 5.56 · 95% CI -307.94 to 319.05
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 27.78 · 95% CI -238.40 to 293.96
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 14.81 · 95% CI -215.01 to 244.64
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 11.11 · 95% CI -302.38 to 324.60
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 38.89 · 95% CI -305.85 to 383.63
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -11.11 · 95% CI -355.85 to 333.63
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 22.22 · 95% CI -322.52 to 366.97
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 44.44 · 95% CI -208.53 to 297.42
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 0.00 · 95% CI -165.61 to 165.61
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 77.78 · 95% CI -17.84 to 173.39
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -11.11 · 95% CI -106.73 to 84.5
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -54.17 · 95% CI -512.66 to 404.33
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -70.00 · 95% CI -143.36 to 3.36
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -33.33 · 95% CI -400.13 to 333.46
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -41.67 · 95% CI -591.86 to 508.53
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -66.67 · 95% CI -66.67 to -66.67
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -83.33 · 95% CI -450.13 to 283.46
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 66.67 · 95% CI -177.86 to 311.2
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 33.33 · 95% CI -333.46 to 400.13
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 25.00 · 95% CI -1258.79 to 1308.79
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 83.33 · 95% CI -283.46 to 450.13
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 33.33 · 95% CI -700.26 to 766.93
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 50.00 · 95% CI -1050.39 to 1150.39
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -16.67 · 95% CI -1850.65 to 1817.32
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 33.33 · 95% CI -700.26 to 766.93
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -16.67 · 95% CI -383.46 to 350.13
SecondaryChange From Baseline in 26-item Pancreatic Cancer-specific Quality of Life Questionnaire (QLQ-PAN26) Score at Day 1 of Every Cycle and End of Study

QLQ-PAN26 consists of 26 questions (Qs) relating to disease symptoms, treatment (Tx) side effects and emotional issues specific to pancreatic cancer (PC). Questions include on altered bowel habits, pain, dietary changes, disease and Tx-related symptoms and issues related to the emotional and social well-being of participants with PC. All 26 Qs are answered on 4-point Likert scale ranging from '1=not at all' to 4='very much' and subsequently transformed into scales that range from 0-100. Higher scores on functioning scales=better functioning; higher scores on the symptom scales=more symptoms.

Time frame:
Phase 2 baseline [Day (D) 1 of Cycle (C)1], Day 1 of all subsequent cycles up to Cycle 14 and end of study (EoS).
Reported as:
Mean · units on a scale
Change From Baseline in 26-item Pancreatic Cancer-specific Quality of Life Questionnaire (QLQ-PAN26) Score at Day 1 of Every Cycle and End of Study
units on a scaleAxitinib + GemcitabineGemcitabine
Pancreatic Pain: Baseline37.52 ± 27.8838.89 ± 21.18
Eating Related Items: Baseline40.40 ± 35.1833.95 ± 27.92
Altered Bowel Habits: Baseline22.32 ± 26.1925.31 ± 28.26
Jaundice: Baseline9.89 ± 18.3415.38 ± 23.06
Body Image: Baseline31.64 ± 29.8026.54 ± 25.84
Health Care Satisfaction: Baseline79.38 ± 27.5769.75 ± 25.33
Sexual Functioning: Baseline44.35 ± 34.4257.97 ± 37.56
Ascites: Baseline37.29 ± 31.0025.93 ± 25.04
Indigestion: Baseline24.86 ± 28.0930.86 ± 34.50
Flatulence: Baseline35.59 ± 32.6739.51 ± 29.29
Cachexia: Baseline33.62 ± 25.4331.48 ± 23.72
Side Effects: Baseline27.78 ± 24.8027.35 ± 21.77
Fear of Future Health: Baseline63.22 ± 31.0359.26 ± 33.76
Ability to Plan Future: Baseline39.55 ± 35.2741.98 ± 36.51
Pancreatic Pain: Change at C2 D1-11.05 ± 25.39-13.64 ± 22.05
Eating Related Items: Change at C2 D1-0.38 ± 34.19-3.79 ± 27.67
Altered Bowel Habits: Change at C2 D18.33 ± 28.19-11.36 ± 22.05
Jaundice: Change at C2 D10.00 ± 20.65-12.70 ± 25.22
Body Image: Change at C2 D17.95 ± 26.53-7.14 ± 25.04
Health Care Satisfaction: Change at C2 D10.39 ± 34.60-3.97 ± 37.60
Sexual Functioning: Change at C2 D1-2.56 ± 22.1418.63 ± 38.59
Ascites: Change at C2 D1-10.85 ± 36.89-3.03 ± 22.79
Indigestion: Change at C2 D1-4.65 ± 24.75-10.61 ± 37.64
Flatulence: Change at C2 D15.30 ± 34.43-9.09 ± 21.04
Cachexia: Change at C2 D19.47 ± 19.15-3.03 ± 17.55
Side Effects: Change at C2 D17.70 ± 16.39-3.17 ± 20.90
Fear of Future Health: Change at C2 D1-2.33 ± 23.450.00 ± 31.62
Ability to Plan Future: Change at C2 D14.55 ± 35.65-1.67 ± 27.52
Pancreatic Pain: Change at C3 D1-8.92 ± 24.62-23.78 ± 20.61
Eating Related Items: Change at C3 D13.07 ± 37.34-10.42 ± 28.46
Altered Bowel Habits: Change at C3 D110.53 ± 31.34-8.33 ± 31.03
Jaundice: Change at C3 D12.19 ± 13.52-9.38 ± 26.51
Body Image: Change at C3 D113.51 ± 30.89-5.21 ± 29.01
Health Care Satisfaction: Change at C3 D1-5.41 ± 40.075.21 ± 24.88
Sexual Functioning: Change at C3 D1-3.13 ± 21.77-4.44 ± 31.79
Ascites: Change at C3 D1-2.63 ± 28.35-4.17 ± 23.96
Indigestion: Change at C3 D1-4.50 ± 34.39-15.56 ± 37.52
Flatulence: Change at C3 D19.65 ± 37.096.25 ± 27.81
Cachexia: Change at C3 D114.47 ± 24.565.21 ± 17.97
Side Effects: Change at C3 D111.55 ± 27.41-7.64 ± 26.28
Fear of Future Health: Change at C3 D1-2.86 ± 34.65-2.22 ± 42.66
Ability to Plan Future: Change at C3 D19.01 ± 43.50-12.50 ± 34.16
Pancreatic Pain: Change at C4 D1-18.30 ± 26.90-14.10 ± 22.92
Eating Related Items: Change at C4 D1-7.47 ± 26.575.13 ± 36.88
Altered Bowel Habits: Change at C4 D116.09 ± 35.213.85 ± 28.99
Jaundice: Change at C4 D11.72 ± 19.59-11.11 ± 16.41
Body Image: Change at C4 D112.82 ± 31.028.97 ± 26.01
Health Care Satisfaction: Change at C4 D1-1.92 ± 49.51-8.97 ± 29.36
Sexual Functioning: Change at C4 D1-5.30 ± 27.88-2.78 ± 40.72
Ascites: Change at C4 D1-6.90 ± 25.792.56 ± 28.74
Indigestion: Change at C4 D1-9.52 ± 33.77-2.56 ± 37.17
Flatulence: Change at C4 D11.15 ± 39.32-2.56 ± 25.32
Cachexia: Change at C4 D19.20 ± 29.07-3.85 ± 24.68
Side Effects: Change at C4 D111.88 ± 28.59-3.24 ± 19.88
Fear of Future Health: Change at C4 D1-2.78 ± 41.615.13 ± 38.12
Ability to Plan Future: Change at C4 D110.26 ± 53.97-5.13 ± 46.84
Pancreatic Pain: Change at C5 D1-7.26 ± 27.99-18.52 ± 24.22
Eating Related Items: Change at C5 D10.00 ± 45.22-7.41 ± 26.50
Altered Bowel Habits: Change at C5 D113.46 ± 30.92-14.81 ± 29.40
Jaundice: Change at C5 D13.85 ± 19.04-20.37 ± 36.11
Body Image: Change at C5 D114.00 ± 28.74-11.11 ± 39.97
Health Care Satisfaction: Change at C5 D1-2.67 ± 51.527.41 ± 34.47
Sexual Functioning: Change at C5 D1-1.75 ± 20.711.85 ± 24.22
Ascites: Change at C5 D1-5.13 ± 24.39-11.11 ± 40.82
Indigestion: Change at C5 D1-3.85 ± 28.79-25.93 ± 49.38
Flatulence: Change at C5 D1-1.33 ± 28.02-11.11 ± 40.82
Cachexia: Change at C5 D110.26 ± 36.84-5.56 ± 18.63
Side Effects: Change at C5 D110.04 ± 28.55-11.73 ± 17.22
Fear of Future Health: Change at C5 D10.00 ± 35.4414.81 ± 29.40
Ability to Plan Future: Change at C5 D120.00 ± 41.94-11.11 ± 16.67
Pancreatic Pain: Change at C6 D1-3.76 ± 24.06-12.50 ± 30.81
Eating Related Items: Change at C6 D1-4.90 ± 50.958.33 ± 21.52
Altered Bowel Habits: Change at C6 D113.73 ± 25.16-8.33 ± 28.87
Jaundice: Change at C6 D11.96 ± 11.61-16.67 ± 45.13
Body Image: Change at C6 D123.96 ± 31.600.00 ± 0.00
Health Care Satisfaction: Change at C6 D1-11.46 ± 42.04-25.00 ± 21.52
Sexual Functioning: Change at C6 D1-7.69 ± 30.14-20.83 ± 49.77
Ascites: Change at C6 D1-1.96 ± 24.92-8.33 ± 31.91
Indigestion: Change at C6 D13.92 ± 35.12-16.67 ± 19.25
Flatulence: Change at C6 D11.96 ± 27.56-8.33 ± 16.67
Cachexia: Change at C6 D14.90 ± 31.05-20.83 ± 15.96
Side Effects: Change at C6 D116.34 ± 30.40-22.22 ± 15.71
Fear of Future Health: Change at C6 D1-4.44 ± 45.190.00 ± 0.00
Ability to Plan Future: Change at C6 D112.50 ± 54.2616.67 ± 63.83
Pancreatic Pain: Change at C7 D1-3.70 ± 22.09-16.67 ± 11.79
Eating Related Items: Change at C7 D1-14.81 ± 31.678.33 ± 11.79
Altered Bowel Habits: Change at C7 D15.56 ± 23.5725.00 ± 58.93
Jaundice: Change at C7 D15.56 ± 11.79-41.67 ± 58.93
Body Image: Change at C7 D116.67 ± 41.67-25.00 ± 58.93
Health Care Satisfaction: Change at C7 D15.56 ± 26.35-33.33 ± 0.00
Sexual Functioning: Change at C7 D1-9.52 ± 18.90-41.67 ± 11.79
Ascites: Change at C7 D10.00 ± 0.000.00 ± 0.00
Indigestion: Change at C7 D1-7.41 ± 22.220.00 ± 0.00
Flatulence: Change at C7 D1-3.70 ± 30.93-16.67 ± 23.57
Cachexia: Change at C7 D15.56 ± 25.00-8.33 ± 35.36
Side Effects: Change at C7 D18.64 ± 25.93-22.22 ± 31.43
Fear of Future Health: Change at C7 D14.17 ± 27.82-16.67 ± 70.71
Ability to Plan Future: Change at C7 D114.81 ± 55.5633.33 ± 47.14
Pancreatic Pain: Change at C8 D1-1.54 ± 25.99-25.00 ± NA
Eating Related Items: Change at C8 D13.70 ± 48.4316.67 ± NA
Altered Bowel Habits: Change at C8 D114.81 ± 22.74-33.33 ± NA
Jaundice: Change at C8 D19.26 ± 12.11-83.33 ± NA
Body Image: Change at C8 D122.22 ± 37.2716.67 ± NA
Health Care Satisfaction: Change at C8 D13.70 ± 27.36-33.33 ± NA
Sexual Functioning: Change at C8 D1-7.14 ± 13.110.00 ± NA
Ascites: Change at C8 D1-3.70 ± 26.060.00 ± NA
Indigestion: Change at C8 D1-7.41 ± 40.060.00 ± NA
Flatulence: Change at C8 D1-11.11 ± 33.33-33.33 ± NA
Cachexia: Change at C8 D111.11 ± 26.35-16.67 ± NA
Side Effects: Change at C8 D111.11 ± 35.140.00 ± NA
Fear of Future Health: Change at C8 D14.17 ± 45.2133.33 ± NA
Ability to Plan Future: Change at C8 D111.11 ± 64.5566.67 ± NA
Pancreatic Pain: Change at C9 D10.00 ± 30.43-16.67 ± NA
Eating Related Items: Change at C9 D114.29 ± 39.000.00 ± NA
Altered Bowel Habits: Change at C9 D123.81 ± 25.20-50.00 ± NA
Jaundice: Change at C9 D19.52 ± 16.27-66.67 ± NA
Body Image: Change at C9 D128.57 ± 35.630.00 ± NA
Health Care Satisfaction: Change at C9 D12.38 ± 24.40-33.33 ± NA
Sexual Functioning: Change at C9 D1-13.33 ± 29.810.00 ± NA
Ascites: Change at C9 D1-11.11 ± 34.4333.33 ± NA
Indigestion: Change at C9 D14.76 ± 35.630.00 ± NA
Flatulence: Change at C9 D114.29 ± 26.230.00 ± NA
Cachexia: Change at C9 D123.81 ± 34.500.00 ± NA
Side Effects: Change at C9 D131.75 ± 33.600.00 ± NA
Fear of Future Health: Change at C9 D1-16.67 ± 40.8233.33 ± NA
Ability to Plan Future: Change at C9 D119.05 ± 42.4133.33 ± NA
Pancreatic Pain: Change at C10 D18.33 ± 25.28-16.67 ± NA
Eating Related Items: Change at C10 D125.00 ± 25.280.00 ± NA
Altered Bowel Habits: Change at C10 D127.78 ± 22.77-50.00 ± NA
Jaundice: Change at C10 D12.78 ± 16.39-83.33 ± NA
Body Image: Change at C10 D125.00 ± 29.340.00 ± NA
Health Care Satisfaction: Change at C10 D113.89 ± 30.58-33.33 ± NA
Sexual Functioning: Change at C10 D1-13.33 ± 29.81-33.33 ± NA
Ascites: Change at C10 D10.00 ± 21.0833.33 ± NA
Indigestion: Change at C10 D127.78 ± 25.090.00 ± NA
Flatulence: Change at C10 D116.67 ± 18.260.00 ± NA
Cachexia: Change at C10 D125.00 ± 39.0916.67 ± NA
Side Effects: Change at C10 D137.04 ± 28.6911.11 ± NA
Fear of Future Health: Change at C10 D10.00 ± 0.0033.33 ± NA
Ability to Plan Future: Change at C10 D133.33 ± 42.1633.33 ± NA
Pancreatic Pain: Change at C11 D15.56 ± 47.39-8.33 ± NA
Eating Related Items: Change at C11 D138.89 ± 53.5833.33 ± NA
Altered Bowel Habits: Change at C11 D150.00 ± 44.10-16.67 ± NA
Jaundice: Change at C11 D116.67 ± 44.10-83.33 ± NA
Body Image: Change at C11 D150.00 ± 44.1016.67 ± NA
Health Care Satisfaction: Change at C11 D127.78 ± 25.46-16.67 ± NA
Sexual Functioning: Change at C11 D1-33.33 ± 47.14-33.33 ± NA
Ascites: Change at C11 D122.22 ± 38.4933.33 ± NA
Indigestion: Change at C11 D111.11 ± 19.250.00 ± NA
Flatulence: Change at C11 D111.11 ± 19.250.00 ± NA
Cachexia: Change at C11 D155.56 ± 25.4616.67 ± NA
Side Effects: Change at C11 D155.56 ± 50.9211.11 ± NA
Fear of Future Health: Change at C11 D10.00 ± 0.0033.33 ± NA
Ability to Plan Future: Change at C11 D144.44 ± 50.9266.67 ± NA
Pancreatic Pain: Change at C12 D1-5.56 ± 20.97—
Eating Related Items: Change at C12 D116.67 ± 16.67—
Altered Bowel Habits: Change at C12 D127.78 ± 34.69—
Jaundice: Change at C12 D10.00 ± 0.00—
Body Image: Change at C12 D116.67 ± 16.67—
Health Care Satisfaction: Change at C12 D1-5.56 ± 41.94—
Sexual Functioning: Change at C12 D10.00 ± 66.67—
Ascites: Change at C12 D1-22.22 ± 19.25—
Indigestion: Change at C12 D10.00 ± 0.00—
Flatulence: Change at C12 D10.00 ± 0.00—
Cachexia: Change at C12 D133.33 ± 28.87—
Side Effects: Change at C12 D1(n=3,0)33.33 ± 40.06—
Fear of Future Health: Change at C12 D10.00 ± 0.00—
Ability to Plan Future: Change at C12 D10.00 ± 0.00—
Pancreatic Pain: Change at C13 D120.83 ± 5.89—
Eating Related Items: Change at C13 D158.33 ± 58.93—
Altered Bowel Habits: Change at C13 D18.33 ± 11.79—
Jaundice: Change at C13 D125.00 ± 35.36—
Body Image: Change at C13 D141.67 ± 58.93—
Health Care Satisfaction: Change at C13 D1-16.67 ± 23.57—
Sexual Functioning: Change at C13 D1-50.00 ± 23.57—
Ascites: Change at C13 D116.67 ± 23.57—
Indigestion: Change at C13 D10.00 ± 0.00—
Flatulence: Change at C13 D116.67 ± 23.57—
Cachexia: Change at C13 D133.33 ± 47.14—
Side Effects: Change at C13 D116.67 ± 7.86—
Fear of Future Health: Change at C13 D10.00 ± 0.00—
Ability to Plan Future: Change at C13 D116.67 ± 23.57—
Pancreatic Pain: Change at C14 D1-8.33 ± NA—
Eating Related Items: Change at C14 D116.67 ± NA—
Altered Bowel Habits: Change at C14 D133.33 ± NA—
Jaundice: Change at C14 D133.33 ± NA—
Body Image: Change at C14 D133.33 ± NA—
Health Care Satisfaction: Change at C14 D10.00 ± NA—
Sexual Functioning: Change at C14 D1-33.33 ± NA—
Ascites: Change at C14 D10.00 ± NA—
Indigestion: Change at C14 D10.00 ± NA—
Flatulence: Change at C14 D133.33 ± NA—
Cachexia: Change at C14 D150.00 ± NA—
Side Effects: Change at C14 D10.00 ± NA—
Fear of Future Health: Change at C14 D10.00 ± NA—
Ability to Plan Future: Change at C14 D10.00 ± NA—
Pancreatic Pain: Change at EoS58.33 ± 35.360.00 ± NA
Eating Related Items: Change at EoS25.00 ± 82.500.00 ± NA
Altered Bowel Habits: Change at EoS83.33 ± 23.570.00 ± NA
Jaundice: Change at EoS8.33 ± 11.790.00 ± NA
Body Image: Change at EoS66.67 ± 0.00-16.67 ± NA
Health Care Satisfaction: Change at EoS0.00 ± NA33.33 ± NA
Sexual Functioning: Change at EoS0.00 ± NA33.33 ± NA
Ascites: Change at EoS33.33 ± 47.1433.33 ± NA
Indigestion: Change at EoS33.33 ± 47.1433.33 ± NA
Flatulence: Change at EoS83.33 ± 23.570.00 ± NA
Cachexia: Change at EoS66.67 ± 0.000.00 ± NA
Side Effects: Change at EoS19.44 ± 90.35-11.11 ± NA
Fear of Future Health: Change at EoS33.33 ± NA-33.33 ± NA
Ability to Plan Future: Change at EoS66.67 ± NA33.33 ± NA
Statistical analysis
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 2.59 · 95% CI -10.11 to 15.29
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 3.41 · 95% CI -13.39 to 20.20
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 19.70 · 95% CI 5.96 to 33.43
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 12.70 · 95% CI 0.93 to 24.47
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 15.10 · 95% CI 1.28 to 28.91
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 4.36 · 95% CI -14.59 to 23.30
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -21.19 · 95% CI -37.53 to -4.85
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -7.82 · 95% CI -25.04 to 9.40
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 5.95 · 95% CI -9.59 to 21.50
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 14.39 · 95% CI -1.61 to 30.40
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 12.50 · 95% CI 2.78 to 22.22
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 10.88 · 95% CI 1.36 to 20.39
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -2.33 · 95% CI -16.36 to 11.71
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 6.21 · 95% CI -11.78 to 24.20
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 14.87 · 95% CI 0.79 to 28.94
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 13.49 · 95% CI -7.45 to 34.42
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 18.86 · 95% CI 0.17 to 37.55
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 11.57 · 95% CI 0.66 to 22.48
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 18.72 · 95% CI 0.49 to 36.95
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -10.61 · 95% CI -32.40 to 11.17
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 1.32 · 95% CI -14.63 to 17.27
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 1.54 · 95% CI -14.70 to 17.78
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 11.05 · 95% CI -10.65 to 32.75
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 3.40 · 95% CI -17.33 to 24.13
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 9.27 · 95% CI -4.40 to 22.93
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 19.19 · 95% CI 2.99 to 35.39
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -0.63 · 95% CI -23.70 to 22.43
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 21.51 · 95% CI -3.10 to 46.12
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -4.19 · 95% CI -21.57 to 13.19
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -12.60 · 95% CI -32.86 to 7.66
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 12.25 · 95% CI -10.33 to 34.82
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 12.84 · 95% CI -0.18 to 25.85
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 3.85 · 95% CI -16.45 to 24.14
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 7.05 · 95% CI -23.23 to 37.34
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -2.53 · 95% CI -26.55 to 21.50
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -9.46 · 95% CI -27.48 to 8.56
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -6.96 · 95% CI -30.62 to 16.70
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 3.71 · 95% CI -20.37 to 27.80
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 13.04 · 95% CI -5.73 to 31.81
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 15.12 · 95% CI -3.23 to 33.46
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -7.91 · 95% CI -36.18 to 20.37
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 15.38 · 95% CI -20.24 to 51.01
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 11.25 · 95% CI -10.09 to 32.59
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 7.41 · 95% CI -25.22 to 40.03
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 28.28 · 95% CI 4.23 to 52.32
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 24.22 · 95% CI 5.09 to 43.34
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 25.11 · 95% CI -0.16 to 50.38
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -10.07 · 95% CI -47.95 to 27.80
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -3.61 · 95% CI -21.78 to 14.57
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 5.98 · 95% CI -17.02 to 28.99
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 22.08 · 95% CI -5.39 to 49.55
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 9.78 · 95% CI -15.33 to 34.89
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 15.81 · 95% CI -10.43 to 42.06
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 21.77 · 95% CI 1.11 to 42.43
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -14.81 · 95% CI -41.91 to 12.28
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 31.11 · 95% CI 1.60 to 60.62
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 8.74 · 95% CI -20.62 to 38.10
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -13.24 · 95% CI -68.52 to 42.05
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 22.06 · 95% CI -7.93 to 52.05
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 18.63 · 95% CI -5.64 to 42.89
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 23.96 · 95% CI -9.93 to 57.84
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 13.54 · 95% CI -32.70 to 59.78
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 13.14 · 95% CI -29.46 to 55.74
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 6.37 · 95% CI -24.04 to 36.79
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 20.59 · 95% CI -17.94 to 59.12
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 10.29 · 95% CI -20.12 to 40.71
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 25.74 · 95% CI -8.22 to 59.69
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 38.56 · 95% CI 5.32 to 71.81
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -4.44 · 95% CI -53.14 to 44.25
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -4.17 · 95% CI -69.90 to 61.57
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 12.96 · 95% CI -24.52 to 50.45
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -23.15 · 95% CI -76.41 to 30.11
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -19.44 · 95% CI -71.89 to 33.00
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 47.22 · 95% CI 7.31 to 87.13
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 41.67 · 95% CI -36.00 to 119.34
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 38.89 · 95% CI -5.05 to 82.83
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 32.14 · 95% CI -2.09 to 66.37
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -7.41 · 95% CI -44.46 to 29.64
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 12.96 · 95% CI -40.45 to 66.37
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 13.89 · 95% CI -32.71 to 60.49
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 30.86 · 95% CI -16.16 to 77.89
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 20.83 · 95% CI -44.95 to 86.62
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -18.52 · 95% CI -115.22 to 78.19
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 23.46 · 95% CI -39.71 to 86.63
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -12.96 · 95% CI -130.69 to 104.76
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 48.15 · 95% CI -7.12 to 103.42
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 92.59 · 95% CI 63.16 to 122.02
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 5.56 · 95% CI -85.03 to 96.14
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 37.04 · 95% CI -29.46 to 103.54
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -7.14 · 95% CI -41.45 to 27.16
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -3.70 · 95% CI -67.04 to 59.64
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -7.41 · 95% CI -104.79 to 89.97
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 22.22 · 95% CI -58.80 to 103.25
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 27.78 · 95% CI -36.28 to 91.83
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 11.11 · 95% CI -74.30 to 96.52
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -29.17 · 95% CI -142.55 to 84.21
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -55.56 · 95% CI -212.46 to 101.35
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 16.67 · 95% CI -62.93 to 96.26
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 14.29 · 95% CI -87.74 to 116.31
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 73.81 · 95% CI 7.90 to 139.72
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 76.19 · 95% CI 33.64 to 118.74
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 28.57 · 95% CI -64.64 to 121.79
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 35.71 · 95% CI -28.11 to 99.53
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -13.33 · 95% CI -104.01 to 77.34
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -44.44 · 95% CI -140.03 to 51.14
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 4.76 · 95% CI -88.45 to 97.98
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 14.29 · 95% CI -54.32 to 82.89
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 23.81 · 95% CI -66.45 to 114.07
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 31.75 · 95% CI -56.14 to 119.63
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -50.00 · 95% CI -163.35 to 63.35
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -14.29 · 95% CI -125.23 to 96.66
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 25.00 · 95% CI -45.18 to 95.18
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 25.00 · 95% CI -45.18 to 95.18
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 77.78 · 95% CI 14.55 to 141.00
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 86.11 · 95% CI 40.61 to 131.61
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 25.00 · 95% CI -56.48 to 106.48
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 47.22 · 95% CI -37.69 to 132.13
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 20.00 · 95% CI -70.68 to 110.68
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -33.33 · 95% CI -91.87 to 25.20
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 27.78 · 95% CI -41.89 to 97.45
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 16.67 · 95% CI -34.03 to 67.36
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 8.33 · 95% CI -100.19 to 116.86
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 25.93 · 95% CI -53.73 to 105.58
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 0.00 · 95% CI -117.07 to 117.07
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 13.89 · 95% CI -221.53 to 249.31
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 5.56 · 95% CI -260.62 to 271.74
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 66.67 · 95% CI -152.41 to 285.75
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 100.00 · 95% CI -119.08 to 319.08
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 33.33 · 95% CI -185.75 to 252.41
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 44.44 · 95% CI -82.04 to 170.93
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 0.00 · 95% CI -733.59 to 733.59
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -11.11 · 95% CI -202.34 to 180.12
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 11.11 · 95% CI -84.50 to 106.73
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 11.11 · 95% CI -84.50 to 106.73
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 38.89 · 95% CI -87.60 to 165.37
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 44.44 · 95% CI -208.53 to 297.42
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): -22.22 · 95% CI -275.19 to 230.75
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 58.33 · 95% CI -491.86 to 608.53
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 25.00 · 95% CI -1258.79 to 1308.79
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 83.33 · 95% CI -283.46 to 450.13
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 8.33 · 95% CI -175.06 to 191.73
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 0.00 · 95% CI -733.59 to 733.59
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 0.00 · 95% CI -733.59 to 733.59
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 83.33 · 95% CI -283.46 to 450.13
  • Axitinib + Gemcitabine vs Gemcitabine · Mean difference (final values): 30.56 · 95% CI -1375.5 to 1436.61

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axitinib + Gemcitabine (Phase 1 Lead-In)—3/8 (37.5%)7/8 (87.5%)
Axitinib + Gemcitabine—35/68 (51.5%)67/68 (98.5%)
Gemcitabine—10/31 (32.3%)26/31 (83.9%)
Most frequent serious events
Showing 10 of 81
Most frequent serious events
EventAxitinib + Gemcitabine (Phase 1 Lead-In)Axitinib + GemcitabineGemcitabine
AnaemiaBlood and lymphatic system disorders1/84/681/31
TinnitusEar and labyrinth disorders1/80/680/31
Multi-organ failureGeneral disorders1/80/680/31
InfectionInfections and infestations1/80/680/31
Platelet count decreasedInvestigations1/80/680/31
PyrexiaGeneral disorders0/81/683/31
Disease progressionGeneral disorders0/86/680/31
DyspnoeaRespiratory, thoracic and mediastinal disorders0/86/680/31
Abdominal painGastrointestinal disorders0/85/680/31
NauseaGastrointestinal disorders0/82/682/31
Most frequent other events
Showing 10 of 276
Most frequent other events
EventAxitinib + Gemcitabine (Phase 1 Lead-In)Axitinib + GemcitabineGemcitabine
FatigueGeneral disorders7/829/6810/31
DiarrhoeaGastrointestinal disorders4/835/688/31
AnaemiaBlood and lymphatic system disorders4/816/687/31
ThrombocytopeniaBlood and lymphatic system disorders4/810/682/31
HypertensionVascular disorders4/816/680/31
NauseaGastrointestinal disorders3/830/6815/31
VomitingGastrointestinal disorders2/829/6812/31
Decreased appetiteMetabolism and nutrition disorders1/829/6810/31
Mucosal inflammationGeneral disorders3/812/682/31
Cytolytic hepatitisHepatobiliary disorders3/81/681/31

Baseline characteristics

Age, Customized
Age, Customized(Participants)Axitinib + Gemcitabine (Phase 1 Lead-In)Axitinib + GemcitabineGemcitabineTotal
18 years to 44 years0246
45 years to 64 years5312056
Greater than or equal to 65 years3361049
Sex: Female, Male
Sex: Female, Male(Participants)Axitinib + Gemcitabine (Phase 1 Lead-In)Axitinib + GemcitabineGemcitabineTotal
Female1341853
Male7351658
08

Study locations

38 sites
  • East Bay Medical Oncology/Hematology Medical Associates Inc.
    Antioch, California 94509, United States
  • Alta Bates Comprehensive Cancer Center
    Berkeley, California 94704, United States
  • Bay Area Cancer Research Group
    Concord, California 94520, United States
  • East Bay Medical Oncology/Hematology Medical Associates, Inc.
    Concord, California 94520, United States
  • Hematology Oncology, P.C.
    Stamford, Connecticut 06902-3628, United States
  • Jackson Memorial Hospital & Clinics
    Miami, Florida 33136, United States
  • University of Miami Hospital & clinics
    Miami, Florida 33136, United States
  • H Lee Moffitt Cancer Center & Research Institute
    Tampa, Florida 33612-9497, United States
  • Maine Center for Cancer Medicine and Blood Disorders
    Biddeford, Maine 04005, United States
  • Maine Center for Cancer Medicine and Blood Disorders
    Brunswick, Maine 04011, United States
  • Maine Center for Cancer Medicine and Blood Disorders
    Scarborough, Maine 04074, United States
  • Arch Medical Services, Inc. d/b/a The Center for Cancer Care and Research
    Saint Louis, Missouri 63141, United States
  • Arch Medical Services, Inc. d/b/a The Center for Cancer Care and Research
    Washington, Missouri 63090, United States
  • Southeast Nebraska Cancer Center, Southeast Nebraska Hematology and Oncology Consultants, P.C.
    Lincoln, Nebraska 68510, United States
  • Piedmont Hematology Oncology Association
    Winston-Salem, North Carolina 27103, United States
  • Piedmont Hematology Oncology Associates
    Winston-Salem, North Carolina 27292, United States
  • University of Wisconsin Hospital and Clinics
    Madison, Wisconsin 53792, United States
  • Universitair Ziekenhuis Gent/Dienst Gastroenterologie
    Gent, 9000, Belgium
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • Cancer Care Manitoba
    Winnipeg, Manitoba R2H 2A6, Canada
  • CancerCare Manitoba
    Winnipeg, Manitoba R3E 0V9, Canada
  • Sault Area Hospital
    Sault Ste Marie, Ontario P6A 2C4, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • CHUM, Hopital Saint-Luc
    Montreal, Quebec H2X 3J4, Canada
  • Service Oncologie Medicale
    Saint-Herblain, Saint Herblain Cedex 44805, France
  • Hopital La Timone
    Marseille, 13005, France
  • Hopital de la Pitie Salpetriere
    Paris Cedex 13, 75651, France
  • Institut Claudius Regaud
    Toulouse, 31052, France
  • Medizinische Klinik mit Schwerpunkt Haematologie und Onkologie, Charité-Universitaetsmedizin Berlin
    Berlin, 13353, Germany
  • Fondazione IRCCS, Istituto Nazionale Tumori, Oncologia Medica B
    Milano, 20133, Italy
  • Unita Operativa, Oncologia Medica, Istituto di Medicina Interna e Geriatria
    Roma, 00168, Italy
  • Hospital Universitario Vall D´Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic I Provincial de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario Virgen Del Rocio
    Sevilla, 41013, Spain
  • Cancer Research Uk Clinical Centre
    Southampton, Hampshire SO16 6YD, United Kingdom
  • Department of Cancer Studies & Molecular Medicine
    Leicester, Leicestershire LE1 5WW, United Kingdom
  • Western General Hospitals Nhs Trust
    Edinburgh, EH4 2XU, United Kingdom
  • Hammersmith Hospital
    London, W12 OHS, United Kingdom
09

References and documents

Publications

  • Spano JP, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, Letourneau R, Bajetta E, Pithavala Y, Bycott P, Trask P, Liau K, Ricart AD, Kim S, Rixe O. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet. 2008 Jun 21;371(9630):2101-8. doi: 10.1016/S0140-6736(08)60661-3. Epub 2008 May 29. PubMed 18514303 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2005 to primary completion in Mar 2008, 32 months.

Results were first posted in Aug 2012, 4 years 5 months after primary completion. A results delay was requested in Mar 2009.

Of 69 industry-sponsored phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 32 months is below that.

Counting every sponsor, half of 394 studies reached it within 57 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 22, 2005
StartActual
Jul 5, 2005
Primary completionActual
Mar 14, 2008
CompletionActual
Mar 14, 2008
Results delay requested
Mar 20, 2009
Results first posted
Aug 24, 2012
Last update
May 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00219557
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 22, 2005
Start date
Jul 5, 2005
Primary completion
Mar 14, 2008
Completion
Mar 14, 2008
Results posted
Aug 24, 2012
Last update
May 14, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion